Benefitting over 150 cancer patients, Jindal IVF, one of North India’s premier Assisted Reproductive Technology (ART) institutions, is gaining recognition for its Fertility Preservation Program, an oncofertility initiative designed to safeguard the reproductive potential of cancer patients before undergoing aggressive treatments such as chemotherapy or radiotherapy.

Since its launch in 2015, the program has supported over 150 individuals, primarily aged between 18 to 30, allowing them to make proactive decisions about their fertility following early-stage cancer diagnoses. Jindal IVF offers a full spectrum of fertility preservation services, including oocyte and embryo freezing for women, and sperm cryopreservation for men, with growing referrals from top oncology centres such as PGIMER, Fortis, MAX, and Tata Memorial.

According to the centre, more than 100 male patients have availed sperm cryopreservation, while approximately 50 women have opted for oocyte freezing. Embryo preservation has emerged as a go-to option for married women preparing to start cancer treatment, reflecting the growing awareness and accessibility of such reproductive interventions.

Dr. Umesh Jindal, Senior Consultant and IVF Specialist at Jindal IVF, emphasised the dual impact of the program, stating, “A cancer diagnosis need not mean the end of one’s parenthood journey. Our program ensures medical, emotional, and ethical support to patients who are fighting both a life-threatening disease and the loss of fertility.” He added that early referral and collaboration with oncologists play a pivotal role in delivering timely interventions.

A landmark case highlights the success of the program—a male patient with testicular cancer opted for sperm freezing before chemotherapy. Two years post-treatment, the frozen sperm was used in an IVF cycle, leading to the successful birth of a healthy baby girl, underscoring the transformative potential of fertility preservation in cancer care.

With a proven track record that includes over 12,000 successful deliveries, 20,000+ IUI procedures, and 15,000+ IVF cycles, Jindal IVF stands out not only for clinical outcomes but also for its pioneering work in areas like the PGT-HLA procedure for Thalassemia major and complex pregnancy management.

As the demand for fertility preservation grows in parallel with cancer survival rates, Jindal IVF is preparing to expand its program through strategic collaborations and joint oncofertility clinics, ensuring holistic and timely care for patients. The program reinforces the institute’s commitment to offering hope and quality of life for young adults confronting the dual challenge of cancer and fertility loss.

Also read: 82% Prefer Diagnostic Centres Over Hospitals in India: ekincare Report

For stakeholders in oncology and reproductive medicine, Jindal IVF’s initiative sets a benchmark for collaborative, patient-centric care and points to the critical need for integrated service pathways in oncofertility going forward.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!